論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	査読あり
表題	Haemophilia and cardiovascular disease in Japan: Low incidence rates from ADVANCE Japan baseline data.
掲載誌名	正式名：Haemophilia : the official journal of the World Federation of Hemophilia 略　 称：Haemophilia ISSNコード：13652516/13518216
掲載区分	国外
巻・号・頁	29(6),pp.1519-1528
著者・共著者	Azusa Nagao, Yushi Chikasawa, Akihiro Sawada, Takeshi Kanematsu, Naoya Yamasaki, Hideyuki Takedani, Masanori Nojima, Teruhisa Fujii, Nobuaki Suzuki, Tadashi Matsushita, Satoshi Higasa, Kagehiro Amano,
発行年月	2023/11
概要	INTRODUCTION:With the increasing life expectancy of people with haemophilia, the risk of cardiovascular disease (CVD) and thrombotic events has become a growing concern. Longitudinal studies on the incidence and risk factors of CVD in this population are limited, and optimal prevention and treatment strategies are yet to be established.AIM:This study aimed to present the baseline data of a prospective longitudinal study focusing on a subset of Japanese patients with haemophilia, specifically investigated the incidence, risk factors and treatment modalities for CVD and thrombotic diseases in people aged 40 years in Japan over 10 years through the ADVANCE Japan study.METHODS:The ADVANCE Japan study is a prospective multicentre cohort study involving 600 adult individuals with haemophilia A/B aged 40 years in Japan. The primary endpoint was the incidence of CVD, with secondary endpoints encompassing anticoagulant use, mortality rates, and comparison with the general population.RESULTS:Baseline data from the 600 participants revealed that thrombotic events occurred in 13 individuals (2.2%), mostly in those with haemophilia A. Atrial fibrillation was observed in 11 participants (1.8%). Hypertension and dyslipidaemia were identified as the prevalent risk factors. Various prophylactic treatments were employed, and no severe bleeding events were observed during the study period.CONCLUSION:This study provides vital baseline data for a 10-year prospective investigation of CVD and thrombotic disease risk in people with haemophilia. These findings will contribute to refining prevention and treatment approaches and improving patients' quality of life.
DOI	10.1111/hae.14876
PMID	37806778